Aug 18 (Reuters) - NRX Pharmaceuticals Inc NRXP.O:
NRX PHARMACEUTICALS, INC. $(NRXP)$ REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
NRX PHARMACEUTICALS INC: BELIEVES THAT ITS CURRENT CASH POSITION WILL SUPPORT OPERATIONS INTO 2026
NRX PHARMACEUTICALS INC: APPLYING FOR A PDUFA FEE WAIVER FOR NRX-101 FROM FDA
Source text: ID:nGNX6F1bbV
Further company coverage: NRXP.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.